Raymond James Financial
CRMD icon

Raymond James Financial’s CorMedix CRMD Stock Holding History

Raymond James Financial’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.5M Buy
446,142
+117,918
+36% +$932K ﹤0.01% 3038
2026
Q1 		$2.23M Sell
328,224
-137,217
-29% -$1.01M ﹤0.01% 3273
2025
Q4 		$5.41M Sell
465,441
-186,546
-29% -$2.06M ﹤0.01% 2448
2025
Q3 		$7.58M Buy
651,987
+564,688
+647% +$6.83M ﹤0.01% 2142
2025
Q2 		$1.08M Sell
87,299
-53,456
-38% -$590K ﹤0.01% 3532
2025
Q1 		$867K Buy
140,755
+25,094
+22% +$260K ﹤0.01% 3592
2024
Q4 		$937K Buy
+115,661
New +$1.16M ﹤0.01% 3493

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Raymond James Financial's CRMD Position: Q2 2026 in Review

Raymond James Financial increased its CorMedix (CRMD) stake by 36% in Q2 2026, buying an estimated $932K and bringing the position to 446,142 shares worth $3.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3038.

Raymond James Financial first reported a position in CRMD in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.58M in Q3 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Raymond James Financial held 446,142 shares of CorMedix worth $3.5M as of Q2 2026.
  • Raymond James Financial bought 117,918 CorMedix shares in Q2 2026, an estimated $932K.
  • CorMedix made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3038 holding.
  • Raymond James Financial first reported a position in CorMedix in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's CorMedix position peaked at $7.58M in Q3 2025.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.